Benzinga · Aug 14, 2026
JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $23 to $20.
OC
NASDAQ · OCS
Oculis Holding AG
Healthcare · Biotechnology
$12.43
Down-$0.54 (-4.16%)
Updated Aug 28, 2026, 12:05 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.09B
- P/E ratio
- -8.07
- Dividend yield
- 0.00%
- 52-week range
- $10.52 – $34.48
- Volume
- 111.45K
- Avg. volume
- 99.02K
Price performance
OCS price history
1M range · 21 trading sessions · Daily adjusted prices
OCS closed at $12.43 after 21 trading sessions, up 10.88% for the selected period.
- Last close
- $12.43
- Period change
- +10.88%
- Period low
- $11.21
- Period high
- $13.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $12.88 | $13.115 | $12.42 | $12.43 | 111.45K |
| Aug 26, 2026 | $12.98 | $13.06 | $12.81 | $12.97 | 161.92K |
| Aug 25, 2026 | $13.25 | $13.42 | $12.90 | $12.96 | 192.37K |
| Aug 24, 2026 | $13.10 | $13.25 | $12.87 | $13.18 | 150.39K |
| Aug 21, 2026 | $13.17 | $13.2746 | $13.00 | $13.085 | 76.46K |
| Aug 20, 2026 | $13.41 | $13.54 | $13.04 | $13.14 | 111.22K |
| Aug 19, 2026 | $13.21 | $13.70 | $13.15 | $13.57 | 272.42K |
| Aug 18, 2026 | $13.07 | $13.20 | $12.8893 | $13.19 | 198.87K |
| Aug 17, 2026 | $12.86 | $13.34 | $12.80 | $13.14 | 220.31K |
| Aug 14, 2026 | $12.84 | $13.09 | $12.5201 | $12.94 | 125.38K |
| Aug 13, 2026 | $12.87 | $13.19 | $12.64 | $12.82 | 193.27K |
| Aug 12, 2026 | $12.91 | $13.25 | $12.83 | $12.89 | 253.15K |
| Aug 11, 2026 | $12.85 | $12.90 | $12.5101 | $12.75 | 143.13K |
| Aug 10, 2026 | $12.31 | $12.9009 | $12.31 | $12.76 | 287.34K |
| Aug 7, 2026 | $12.95 | $13.28 | $12.41 | $12.68 | 370.88K |
| Aug 6, 2026 | $11.96 | $12.51 | $11.82 | $12.38 | 264.92K |
| Aug 5, 2026 | $12.10 | $12.415 | $11.8737 | $12.07 | 579.29K |
| Aug 4, 2026 | $12.07 | $12.36 | $11.885 | $11.99 | 310.99K |
| Aug 3, 2026 | $11.95 | $12.15 | $11.67 | $11.89 | 295.73K |
| Jul 31, 2026 | $11.34 | $11.35 | $10.87 | $11.31 | 204.89K |
| Jul 30, 2026 | $10.84 | $11.51 | $10.73 | $11.21 | 474.67K |
Latest OCS news
The latest Smart Investors Daily articles mentioning OCS.
Stock researchCompany · Overview
OCS research
Overview
Company profile and research snapshot.
Company profile
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $43.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 3, 2026 | JP Morgan | Overweight | — |
| Jun 2, 2026 | Baird | Outperform | — |
| Jun 1, 2026 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 10, 2026
Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor
Oculis Holding (OCS) has agreed to acquire all of Accure Therapeutics' worldwide development and com
Yahoo · Aug 10, 2026
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up to 2 years, or vesting upon achievement of development and regulatory milestonesPrivosegtor, a neuroprotective drug candidate, is currently being investigated in registrational trials with initial indications
Benzinga · Aug 10, 2026
Oculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
